Lenvatinib plus immunotherapy with TACE versus standard TACE
Part of Cancer, Digestive system clinical trials.
This study compares a stronger treatment plan (lenvatinib plus sintilimab plus TACE) against a standard plan (lenvatinib plus TACE) for advanced liver cancer. It aims to see which plan works better to control tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (HCC), confirmed by biopsy/samples or by a clear clinical diagnosis
- Your cancer can be treated with TACE and you have at least one measurable liver tumor seen on scans
- Your liver function is in the Child-Pugh A or B range
- You feel able to do daily activities most of the time (ECOG 0–1) and are expected to live at least 3 months
- Your liver cancer can’t involve blocked portal veins in a way that blocks both sides (unless special collateral vessels are present)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for liver cancer (HCC) that has stopped responding to TACE. One group gets lenvatinib (a targeted therapy pill) plus SIRT (internal radiation beads placed in the liver), and the other gets lenvatinib alone. The goal is to see which combination works better.
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
This Phase 3 trial compares lenvatinib plus implanted radiation seeds versus lenvatinib alone in people with liver cancer that no longer responds to TACE. It aims to improve how long patients can control the cancer inside the liver.
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This Phase 3 trial tests whether combining several treatments—SBRT (targeted radiation), lenvatinib (an oral anti-cancer medicine), and TACE (a procedure that blocks blood supply to the tumor)—can work better for people with advanced primary liver cancer. It may help shrink tumors and improve survival compared with standard approaches.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.